Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls
Sponsor: Calmy Alexandra
Summary
The purpose of this study is to evaluate the efficacy and safety of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in older people (\> 50 years) living with HIV (PLWH) compared to age-matched healthy adults over a 1-year period.
Official title: Immune Response to the Recombinant Zoster Vaccine in People Living With HIV Over 50 Years of Age Compared to Non-HIV Age- and Gender-matched Controls - The Shingr'HIV Phase IV Multicenter Study
Key Details
Gender
All
Age Range
50 Years - 95 Years
Study Type
INTERVENTIONAL
Enrollment
225
Start Date
2022-12-14
Completion Date
2026-03-31
Last Updated
2025-09-05
Healthy Volunteers
Yes
Conditions
Interventions
Recombinant Zoster Vaccine
Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
Locations (10)
Hôpital Saint-André, CHU de Bordeaux
Bordeaux, Bordeaux, France
SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin
Bordeaux, France, France
CHU de Bordeaux - Hôpital Haut-Lévèque
Pessac, Gironde, France
University Hospital Basel
Basel, Basel, Switzerland
Bern University Hospital (Inselspital)
Bern, Canton of Bern, Switzerland
University Hospitals of Geneva
Geneva, Canton of Geneva, Switzerland
Kantonsspital
Sankt Gallen, Canton of St. Gallen, Switzerland
Centre Hospitalier Universitaire Vaudoise (CHUV)
Lausanne, Canton of Vaud, Switzerland
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Ente Ospedaliero Cantonale
Lugano, Canton Ticino, Switzerland